- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | HCW Biologics, Inc: HCW Biologics Inc. Received NASDAQ Staff Determination Letter | 60 | GlobeNewswire (Europe) | Company Expected Notice for Continued Deficiency and Delist Letter from the Nasdaq Stock Market Company Intends to Request Hearing to Appeal in a Timely Manner MIRAMAR, Fla., Dec. 23, 2024 (GLOBE... ► Artikel lesen | |
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| Mo | HCW Biologics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.11. | HCW Biologics Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 19.11. | HCW Biologics announces pricing of $6.9M registered direct offering, concurrent private placement | 5 | Seeking Alpha | ||
| 19.11. | HCW Biologics, Inc: HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules | 15 | GlobeNewswire (USA) | ||
| 18.11. | HCWB-Aktie erreicht 52-Wochen-Hoch bei 1,97 US-Dollar | 3 | Investing.com Deutsch | ||
| 18.11. | HCWB stock touches 52-week high at $1.97 amid robust gains | 2 | Investing.com | ||
| 18.11. | Why Is Penny Stock HCW Biologics Surging On Monday? | 2 | Benzinga.com | ||
| 18.11. | HCW Biologics unterzeichnet Lizenzvertrag mit WY Biotech | 7 | Investing.com Deutsch | ||
| 18.11. | HCW Biologics signs licensing deal with WY Biotech | 3 | Investing.com | ||
| 18.11. | HCW Biologics, Inc: HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate | 4 | GlobeNewswire (USA) | ||
| 15.11. | HCW Biologics reports Q3 results | 4 | Seeking Alpha | ||
| 14.11. | HCW Biologics, Inc: HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights | 323 | GlobeNewswire (Europe) | MIRAMAR, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing... ► Artikel lesen | |
| 14.11. | HCW Biologics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.11. | HCW Biologics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.11. | HCWB-Aktie erreicht 52-Wochen-Tief bei 0,4 US-Dollar | 2 | Investing.com Deutsch | ||
| 08.11. | HCWB stock touches 52-week low at $0.4 amid market challenges | 1 | Investing.com | ||
| 21.09. | HCW Biologics changes auditor, cites no disagreements | 1 | Investing.com | ||
| 20.09. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.08. | HCW Biologics reports Q2 results | 1 | Seeking Alpha |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,402 | -0,99 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,950 | -1,65 % | Ginkgo Bioworks Reports Third Quarter 2024 Financial Results | Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions
Ginkgo... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,270 | 0,00 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,740 | 0,00 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| CHIMERIX | 2,870 | -1,03 % | Chimerix, Inc.: Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End | Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data | ||
| ARCTURUS THERAPEUTICS | 16,340 | 0,00 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,881 | 0,00 % | Assertio Holdings, Inc.: Assertio Announces Results of Rolvedon (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study | LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,390 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 5,980 | 0,00 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| PURPLE BIOTECH | 3,840 | 0,00 % | Purple Biotech Ltd.: Purple Biotech Reports Third Quarter 2024 Financial Results | Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,430 | 0,00 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,300 | -1,81 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,785 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen |
HCW BIOLOGICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,390 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.
